


AMPLATZER™ SEPTAL OCCLUDER SAFETY



KEY MESSAGES

- The Amplatzer™ Septal Occluder (ASO) is a safe, effective, and reliable treatment option for the transcatheter closure of the secundum atrial septal defect (ASD).
- It is supported by over 20-years of clinical experience and has the largest body of safety and effectiveness data than any other transcatheter device occluder.
- Adoption of ASO is wide despite rare adverse events.

PERSPECTIVE

The ASO was the first transcatheter ASD occlusion device commercially available as a safe and effective treatment alternative to surgical ASD closure, receiving CE mark approval in 1998 and FDA approval in 2001. It is the most widely used transcatheter ASD occlusion device, amassing 750 peer reviewed articles, supporting its safety and effectiveness.¹ Consequently, transcatheter device closure has become the current standard of care for secundum ASD closure of appropriate anatomy.^{2,3}

ASO SAFETY & EFFECTIVENESS

With over 20 years of commercialization and over 430,000 devices implanted, the ASO has the longest history and largest body of clinical evidence compared to any other device occluder.⁴ Compared to much smaller data sets from other device occluders, safety and effectiveness data for the ASO device remains unmatched and allows for more robust assessment of complication rates.

After decades of clinical and commercial use, transcatheter device occluders, in particular the ASO, have become as effective and safer than traditional surgical closure of the

ASD. European guidelines state that transcatheter device closure is the method of choice for secundum ASD closure of appropriate anatomies.³ Surgery and transcatheter intervention have reported comparable success rates and mortality, however morbidity was lower and hospital stay shorter with catheter intervention.³ The US AHA/ACC guidelines hold both therapeutic approaches at parity for adults with isolated ASD accompanied by clinically impaired functional capacity, right heart enlargement, and shunting² [TABLE 1].

TABLE 1: ASD TREATMENT GUIDELINES

AUTHORS	CLASS OF RECOMMENDATION	LEVEL OF EVIDENCE	RECOMMENDATIONS
2010 ESC Guidelines ³	I	B	Patients with significant shunt (signs of RV volume overload) and PVR <5 WU should undergo ASD closure regardless of symptom
	I	C	Device closure is the treatment of choice when applicable.
2018 ACHD Guidelines ²	I	B-NR	In adults with isolated secundum ASD causing impaired functional capacity , right atrial and/or RV enlargement, and net left-to-right shunt sufficiently large to cause physiological sequelae (e.g., pulmonary-systemic blood flow ratio [Qp:Qs] ≥1.5:1) without cyanosis at rest or during exercise, transcatheter or surgical closure to reduce RV volume and improve exercise tolerance is recommended , provided that systolic PA pressure is less than 50% of systolic systemic pressure and pulmonary vascular resistance is less than one third of the systemic vascular resistance.

NR: Non-Randomized



The guidelines reflect acceptance of transcatheter intervention compared to surgery. Further, a meta-analysis of 13 studies summarizing ASD closure by surgery (1,270 patients) or transcatheter device (1,812) reported lower post-procedural and major complications rates compared to the surgical group (6.6% vs. 31.0% and 1.9% vs. 6.8% respectively).⁵ The ASO was the main device used in 12 of the 13 studies. Patients treated surgically had a 5.4x and 3.8x higher risk of total and major complications respectively relative to transcatheter treatment [FIGURE 1].

ASD closure outcomes are best when repair is done at an age less than 25.³ Studies have attested to the ASO as an ideal treatment for this important patient group. An observational study from pediatric cardiology databases in 375 patients, showed no difference in outcomes between transcatheter

and surgery cohorts with regard to survival, functional capacity, arrhythmias or neurological events (follow up 5-20 yrs, median 10 yrs).⁶ Despite better outcomes at younger ages, patients benefit from closure at any age with regard to morbidity (exercise capacity, shortness of breath, right heart failure), particularly when performed with a transcatheter device.³

A retrospective multicenter study of 1,395 children implanted with the ASO reported a procedure success rate was 95.3%, with failed implantations were most often to unsuitable anatomy.⁷ No deaths were reported during follow up (median 3.5yrs) and the complication rate was low at 1.04%. Overall, probability of complication free survival at 12, 60, and 120 months was 99.2 ± 0.2%, 99.1 ± 0.2%, and 98.6 ± 0.6%, respectively.

FIGURE 1: MAJOR COMPLICATIONS OF ASD CLOSURE: SURGICAL V TRANSCATHETER APPROACHES⁵




TABLE 2: SUMMARY OF PEDIATRIC ARTICLES

	PATIENTS (N)	TECHNICAL SUCCESS RATE	COMPLETE CLOSURE RATE	MINOR COMPLICATIONS*	SERIOUS COMPLICATIONS*
Omeish A, Hijazi ZM, 2001 ⁸	3535	98%	100%	2.8%	0.3%
Everett AD, Jennings J, Sibinga E, et al 2009 ⁹	478	96%	99%	4.8%	1.1%
Latiff HA, Alwi M, Samion H, et al. 2002 ¹⁰	190	100%	99%	2.1%	0%
Faella HJ, Sciegata AM, Alonso JL, et al. 2003 ¹¹	109	94%	100%	3.9%	1.0%
Masura J, Gavara P, Podnar T, 2005 ¹²	151	100%	100%	NA	0%
El-Said H, Hegde S, Foerster S, et al 2015 ¹³	688	NA	95%	6.8%	4.7%
Nir-David Y, Mainzer G, Tal R, et al 2017 ¹⁴	110	100%	97.2%	0	0
Putra ST, Djer MM, Idris NS, et al 2015 ¹⁵	152	99.1%	100%	6.0%	1.3%

TABLE 3: SUMMARY OF ADULT ARTICLES

	PATIENTS (N)	TECHNICAL SUCCESS RATE	COMPLETE CLOSURE RATE	MINOR COMPLICATIONS*	SERIOUS COMPLICATIONS*
Omeish A, Hijazi ZM, 2001 ⁸	3535	98%	100%	2.8%	0.3%
Majunke N, Bialkowski J, Wilson N, et al 2009 ¹⁶	650	99%	96%	NA	NA
Patel A, Lopez K, Banerjee A, et al 2007 ¹⁷	113	99%	90%	2.7%	0.9%
Faella HJ, Sciegata AM, Alonso JL, et al. 2003 ¹¹	109	94%	100%	3.9%	1.0%
Spies C, Timmermanns I, Schrader R 2007 ¹⁸	166	98%	98%	6.5%	0%
Turner DR, Owada CY, Sang CJ Jr, et al 2017 ¹⁹	1,000	NA	97.9%	5.4%	0.65%
Astarcioğlu MA, Kalcik M, Sen T, et al 2015 ²⁰	125	100%	100%	15.2%	0
Godart F, Houejeh A, Recher M, et al 2015 ²¹	131	87.8%	89%	8.4%	1.5%
Kijima Y, Akagi T, Takaya T, et al 2016 ²²	463	98%	88%	5.6%	6%
Snijder RJ, Suttorp MJ, Berg JM, et al 2015 ²³	104	98.1%	NA	8.7%	NA

*Minor and serious complications are not defined the same way across all referenced studies

NOTE: Results from clinical trials are not directly comparable. Information provided for educational purposes only.

ASO ADVANTAGE AND RISKS

The body of evidence associated with the ASO has allowed rare adverse events to be detected because of the extensive volume of treated cases. Permanent cardiac implants, such as the ASO, can be associated with long term arrhythmias, thrombo-embolism and cardiac tissue injuries.²⁴ These rates associated with the ASO are very low, and consistent across multiple studies.

Device embolization The ASO is easily retrieved until its release from the delivery cable, minimizing malpositioning or embolization.⁸ A survey of ASO proctors reported an ASO-embolization rate of 0.55% (21/3,842) with no embolization-related deaths.²⁵ All 21 embolized devices were successfully retrieved by transcatheter means (15) or by surgery (6).

Rhythm disturbances A study in 650 adult patients reported new onset atrial fibrillation of 4.5%.¹⁶ However, a long term study showed similar incidence of late arrhythmias among transcatheter occlusion devices and surgical occlusion, implicating the act of defect closure itself rather than closure method.⁵

Cardiac erosion is a rare, serious complication, resulting from device abrasion through the atrial wall into the aorta and/or pericardial space. Reported ASO erosion rates are low at 0.043% - 0.3%.^{26, 27} Analyses of adjudicated ASO erosion cases identified rim deficiency, device oversizing, and low patient weight to device size ratio as possible risk factors.²⁶ Conclusive determination of root causes of cardiac erosion remains challenging due to patient heterogeneity and infrequent occurrence.

There have been recent erosion cases reported with the Figulla Flex II (Occlutech) device.²⁸ However, incidence rates for this and other occluders are not yet precise given shorter overall clinical and commercial experiences compared to the ASO.

With its extensive commercial coverage, Abbott works with regulatory agencies to ensure the latest safety data is being reported and reflected in product guidance. While there have been other device occluders commercialized, the ASO is the only device that has remained in the market for over 20 years with wide adoption, attesting to the safety and effectiveness of the product and therapy.

CONCLUSION

Clinical practice guidelines indicate that device closure is the treatment of choice for the repair of the ASD. As the device occluder with the largest body of evidence and the most extensive clinical and commercial experience, the Amplatzer™ Septal Occluder is the ideal treatment option for the closure of the secundum ASD.

REFERENCES

1. PubMed (2018, Mar.) Retrieved from www.pubmed.gov
2. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2018;000:e000–e000. doi: 10.1161/CIR.0000000000000603
3. Baumgartner H, Bonhoeffer P, De Groot N, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010) The Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC). *European Heart Journal* (2010) 31, 2915–2957 doi:10.1093/eurheartj/ehq249
4. Data on file at Abbott
5. Butera G, Biondi-Zoccai G, Sangiorgi G, et al. Percutaneous versus surgical closure of secundum atrial septal defects: a systematic review and meta-analysis of currently available clinical evidence. *EuroIntervention* 2011;7:377-385
6. Kutty S, Hazeem A, Brown K. Long Term (5- to 20- Year) Outcomes after transcatheter or surgical treatment of hemodynamically significant isolated secundum atrial septal defect. *Am J Cardiol* 2012;109:1348-1352
7. Jalal Z, Hascoet S, Gronier C, et al. Long-Term Outcomes After Percutaneous Closure of Ostium Secundum Atrial Septal Defect in the Young A Nationwide Cohort Study. *J Am Coll Cardiol Intv* 2018;11:795–804. <https://doi.org/10.1016/j.jcin.2018.01.262>
8. Omeish A, Hijazi ZM. Transcatheter closure of atrial septal defects in children & adults using the Amplatzer Septal Occluder. *J Interv Cardiol*. 2001;14:37-44
9. Everett AD, Jennings J, Sibinga E, et al. Community use of the AMPLATZER atrial septal defect occluder: results of the multicenter MAGIC atrial septal defect study. *Pediatr Cardiol*. 2009;30:240-247.
10. Latif HA, Alwi M, Samion H, et al. Transcatheter closure of defects within the oval fossa using the Amplatzer Septal Occluder. *Cardiol Young*. 2002;12:224-228.
11. Faella HJ, Sciegata AM, Alonso JL, et al. ASD closure with the Amplatzer device. *J Interv Cardiol*. 2003;16:393-397.
12. Masura J, Gavara P, Podnar T. Long-term outcome of transcatheter secundum-type atrial septal defect closure using Amplatzer Septal Occluders. *J Am Coll Cardiol*. 2005;45:505-507.
13. El-Said H, Hegde S, Foerster S, et al. Device therapy for atrial septal defects in a multicenter cohort: acute outcomes and adverse events. *Catheter Cardiovasc Interv*. 2015;85:227-233.
14. Nir-David Y, Mainzer G, Tal R, et al. Comparing the performance of Amplatzer® and Occlutech® Figulla® Septal Occluders: the pediatric point of view. A retrospective study. *Isr Med Assoc J*. 2017;19:557-561.
15. Putra ST, Djer MM, Idris NS, et al. Transcatheter closure of atrial septal defects in a center with limited resources: outcomes and short term follow-up. *Iran J Pediatr*. 2015;25:e3906.
16. Majunke N, Bialkowski J, Wilson N, et al. Closure of atrial septal defect with the Amplatzer Septal Occluder in adults. *Am J Cardiol*. 2009;103:550-554.
17. Patel A, Lopez K, Banerjee A, et al. Transcatheter closure of atrial septal defects in adults ≥ 40 years of age: immediate and follow-up results. *J Interventional Cardiol*. 2007;20:82-88.
18. Spies C, Timmermanns I, Schrader R. Transcatheter closure of secundum atrial septal defects in adults with the Amplatzer Septal Occluder: intermediate and long-term results. *Clin Res Cardiol*. 2007;96:340-346.
19. Turner DR, Owada CY, Sang CJ Jr, et al. Closure of secundum atrial septal defects with the Amplatzer Septal Occluder: a prospective, multicenter, post-approval study. *Circ Cardiovasc Interv*. 2017;10
20. Astarcioglu MA, Kalcik M, Sen T, et al. Ceraflex versus Amplatzer occluder for secundum atrial septal defect closure. Multicenter clinical experience. *Herz*. 2015;40(Suppl 2):146-150.
21. Godart F, Houeijeh A, Recher M, et al. Transcatheter closure of atrial septal defect with the Figulla® ASD Occluder: a comparative study with the Amplatzer® Septal Occluder. *Arch Cardiovasc Dis*. 2015;108:57-63.
22. Kijima Y, Akagi T, Takaya T, et al. Deficient surrounding rims in patients undergoing transcatheter atrial septal defect closure. *J Am Soc Echocardiogr*. 2016;29:768-776.
23. Snijder RJ, Suttorp MJ, Berg JM, et al. Percutaneous closure of secundum type atrial septal defects: more than 5-year follow-up. *World J Cardiol*. 2015;7:150-156.
24. Alnasser S, Lee D, Austin P, et al. Long term outcomes among adults post transcatheter atrial septal defect closure: Systematic review and meta-analysis. *International Journal of Cardiology* 270 (2018) 126–132
25. Levi D and Moore J. Embolization and Retrieval of the Amplatzer Septal Occluder. *Catheterization and Cardiovascular Interventions* 61:543-547 (2004)
26. McElhinney DB, Quartermain MD, Kenny D, et al. Relative risk factors for cardiac erosion following transcatheter closure of atrial septal defects: a case-control study. *Circulation*. 2016;133:1738-1746.
27. Crawford G, Brindis R, Krucoff M, et al. Percutaneous Atrial Septal Occluder Devices and Cardiac Erosion: A Review of the Literature. *Catheterization and Cardiovascular Interventions* 80:157–167 (2012)
28. Hijazi ZM. The Pediatric and Adult Interventional Cardiac Symposium (PICS/AICS) 21st Annual Meeting – Las Vegas, Nevada, September 5-8, 2018. *Structural Heart Disease* 2018;4(4):114–206. DOI: 10.12945/j.jshd.2018.020.18



IMPORTANT SAFETY INFORMATION

AMPLATZER™ SEPTAL OCCLUDER

**Rx
ONLY**

INDICATIONS FOR USE

The AMPLATZER™ Septal Occluder is a percutaneous, transcatheter, atrial septal defect closure device intended for the occlusion of atrial septal defects (ASD) in secundum position or patients who have undergone a fenestrated Fontan procedure and who now require closure of the fenestration.

Patients indicated for ASD closure have echocardiographic evidence of ostium secundum atrial septal defect and clinical evidence of right ventricular volume overload (such as, 1.5:1 degree of left-to-right shunt or RV enlargement).

CONTRAINDICATIONS

The AMPLATZER™ Septal Occluder is contraindicated for the following: Any patient known to have extensive congenital cardiac anomaly which can only be adequately repaired by way of cardiac surgery; Any patient known to have sepsis within 1 month prior to implantation, or any systemic infection that cannot be successfully treated prior to device placement; Any patient known to have a bleeding disorder, untreated ulcer, or any other contraindications to aspirin therapy, unless another antiplatelet agent can be administered for 6 months; Any patient known to have a demonstrated intracardiac thrombi on echocardiography (especially left atrial or left atrial appendage thrombi); Any patient whose size (such as, too small for transesophageal echocardiography probe, catheter size) or condition (active infection, etc.) would cause the patient to be a poor candidate for cardiac catheterization; Any patient where the margins of the defect are less than 5 mm to the coronary sinus, inferior vena cava rim, AV valves, or right upper lobe pulmonary vein.

POTENTIAL COMPLICATIONS AND ADVERSE EVENTS

Potential adverse events may occur during or after a procedure placing this device may include, but are not limited to: Air embolus; Allergic dye reaction; Anesthesia reactions; Apnea; Arrhythmia; Cardiac tamponade; Death; Embolization; Fever Hypertension/hypotension; Infection including endocarditis; Need for surgery; Pericardial effusion; Perforation of vessel or myocardium; Pseudoaneurysm including blood loss requiring transfusion; Stroke; Tissue erosion; Thrombus formation on discs; Valvular regurgitation

CAUTION:

This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photo(s) on file at Abbott.

Abbott

3200 Lakeside Dr, Santa Clara, CA 95054, USA, Tel: 1.800.227.9902

www.structuralheart.abbott

[™] Indicates a trademark of the Abbott Group of Companies.

‡ Indicates a third party trademark, which is property of its respective owner.

© 2022 Abbott. All rights reserved. MAT-2117097 v1.0 | Item approved for U.S. use only

